Form D · Biotechnology
Sernova Biotherapeutics Inc.
Mississauga, A6 · CIK 0002102368
Offering snapshot reported Feb 5, 2026 · SEC filing
- Reported sold
- $345K Offering amount: $843K
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 31, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 5, 2026 | Initial | $344,514 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-572557
Total amount is the total price of the Units issued (2,541,680 x C$0.19) + the aggregate exercise price of the warrants (1,270,840 x C$0.25) and (1,270,840 x C$0.30). Converted at C$1: US$0.7134. There is no guarantee the warrants will be exercised.
Source: Form D, filed Feb 5, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Brooks | Director |
| David Burke | Executive |
| Tanya Lewis | Director |
| Bernd Muehlenweg | Director |
| James Parsons | Executive |
| David Paterson | Director |
| Jonathan Rigby | Director, Executive |
| Marylyn Rigby | Executive |
| Steven Sangha | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Po 29592 Rpo Central Parkway
Mississauga, A6, L5A4H2
Mississauga, A6, L5A4H2